A Phase 2 interventional study of larazotide acetate and Placebo in Celiac Disease, sponsored by 9 Meters Biopharma, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-09-12.
Sponsored by 9 Meters Biopharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.
Among the 103 studies in Celiac Disease with a site in United States, this one is the 25th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2006, is one of 21 in phase 2, and was the 2nd registered.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
Browse Celiac Disease studies →16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:
Nielsen Fernandez-Becker · Sites in United States
Ages 18+
Chugai Pharmaceutical · Sites in United States, Australia, New Zealand
Ages 18–75
Joined Bio · Sites in United States
Ages 18–90 · Healthy volunteers
Columbia University · Sites in United States
Ages 18–75
Luventix, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 2 · Phase 4 2
First in 1995; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is above the median of 50 across 215 interventional studies indexed under Celiac Disease.
Median enrollment 46 across the 68 interventional studies, 175 across the 35 observational. Of the 74 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
9 Meters Biopharma, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
9 Meters Biopharma, Inc. has 8 studies filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Celiac Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06310291Barinthus BiotherapeuticsVTP-1000 in Adults With Celiac Disease | 2026-11 |
| NCT06908057AdventHealth Translational Research InstituteAccessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | 2026-12 |
| NCT05680012University of ChicagoTissue Destruction and Healing in Celiac Disease | 2027-05-01 |
| NCT07377565Nielsen Fernandez-BeckerA First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease | 2027-06-01 |
| NCT07239336Chugai PharmaceuticalStudy of DONQ52 in Active Celiac Disease | 2027-06-15 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Celiac Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was run to determine the safety, tolerance, and efficacy of multiple doses of larazotide acetate in subjects with celiac disease following a gluten challenge.
CLIN1001-004 was a randomized, double-blind, placebo controlled, dose-ranging, 7-arm, multicenter study with a gluten challenge. The objects were multiple dose safety and tolerance; efficacy (intestinal permeability [change in urinary LAMA ratio] and disease signs and symptoms) following gluten challenge.
Following a 21-day screening period, subjects were randomized to one of seven treatments groups: four groups received larazotide acetate (0.25 mg, 1 mg, 4 mg or 8 mg TID) along with an 800 mg gluten challenge, one group received placebo with an 800 mg gluten challenge, a safety control arm received the highest dose of larazotide acetate (8 mg TID) and gluten placebo and the last group received drug placebo and gluten placebo. The gluten challenge was administered as capsules (800 mg TID) with each main meal for a total of 2.4 g daily. Drug or drug placebo was administered TID 15 minutes prior to each main meal. Subjects received their assigned treatments for two weeks (Day 0 through Day 14) and came to clinic for a follow-up visit one week later (Day 21). Subjects remained on their gluten-free diet for the duration of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo TID + gluten 800 mg TID administered orally in capsules
Drug: Placebo
placebo TID + gluten placebo TID administered orally in capsules
Drug: Placebo
Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
Drug: larazotide acetate
Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
Drug: larazotide acetate
Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
Drug: larazotide acetate
Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
Drug: larazotide acetate
Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
Drug: larazotide acetate
capsule
Also known as: AT-1001, INN-202
capsule
To demonstrate the safety and tolerability of multiple, oral doses of larazotide acetate in celiac disease subjects that maintain a gluten-free diet.
Safety endpoints assessed in this study were adverse events, vital signs, hematology, clinical chemistry, urinalysis and ECG
Time frame: Safety measurements were performed at Screening and at Day 0, 7, 14, and 21 ('End of Study'). Any change from baseline value was calculated at each subsequent visit until "End of Study" (Day 21).
To evaluate the efficacy of multiple dose levels of larazotide acetate in preventing intestinal permeability changes induced by gluten challenge
The primary efficacy outcome was the Day 0-to-Day 14 change in urinary LAMA ratio ( a measure of intestinal permeability) as a response to gluten
Time frame: On Days 0, 6, 13, and 20 subjects drank a solution of lactulose and mannitol. Subject's urine was collected during the day on Day 0 and overnight prior to subsequent visits and analyzed for LAMA recoveries via standardized methodologies.
Changes in daily and weekly reported health outcomes
Health outcomes were assessed using a daily symptom diary; a weekly PGWBI and a weekly GSRS
Time frame: Symptom diary - daily; PGWBI - weekly; GSRS - weekly
Changes in urinary LAMA ratios between Day 0 to Day 7
See Primary Outcome Measure No. 2
Time frame: See Primary Outcome Measure No. 2
Changes in urinary lactulose fractional excretion between Day 0 to Day 7 to Day 14
See Primary Outcome Measure No. 2
Time frame: See Primary Outcome Measure No. 2
Changes in urinary mannitol fractional excretion between Day 0 to Day 7 to Day 14
See Primary Outcome Measure No. 2
Time frame: See Primary Outcome Measure No. 2
Change in urinary nitrite / nitrate levels from Day 0 to Day 14
Nitrite/nitrate levels were assessed for correlation to the measures of intestinal permeability
Time frame: Day 0 and Day 14
Change in anti-tTG levels from Screening to Day 21
Changes between screening and Day 21 anti-tTG levels were assessed for correlation to the measures of intestinal permeability
Time frame: Screening and Day 21
Change in cell markers and cytokines from PBMCs
Serum cytokine and cell surface marker determinations were assessed for correlation to the measures of intestinal permeability
Time frame: Days 0, 7, 14 and 21
Changes in zonulin level
Serum zonulin levels were assessed for correlation to the measures of intestinal permeability
Time frame: Days 0, 7, 14 and 21
Ran from Sep 2006 to primary completion in Mar 2007, 5 months.
Of 24 phase 2 interventional studies under Celiac Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 28. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Larazotide acetate
9 Meters Biopharma, Inc.